Compare Prostate Cancer Treatments

Comparing Prostate Cancer Treatments begins by gathering information about your Prostate Cancer Diagnosis. Following tests, your Doctor will provide three elements that describe your prostate cancer. Your PSA, Stage and Gleason Score. These three elements help you determine your risk group. Find and select your Risk Group in the table at the top of the page. This process takes you to the comparing prostate cancer treatments page, where you can select different treatments for prostate cancer and graphically see their effectiveness over time.

Select Your Risk Group

Low Risk

PSA less than 10
Gleason Score less than 7
Clinical Stage is T1c to T2a

Intermediate Risk

PSA greater than 10 less than 20
Gleason Score is 7
Clinical Stage is T2b

High Risk

PSA greater than 20
Gleason Score is 8 to 10
Clinical Stage is T2c to T3c

Prostate Cancer Free

Thirty Six Prostate Cancer Experts have analyzed the treatment outcomes of over 100,000 patients across the globe, following these patients for up to 15 years. The success of a treatment is determined by monitoring PSA for years after treatment. This data is presented to you, so you can see which treatments leave patients prostate cancer free. Watch this video to learn more.

We review the research so you don't have to.









An international team of 36 experts took on the task of Comparing Prostate Cancer Treatments for more than 100,000 patients over 15 years. The goal of the study was to determine who remained prostate cancer free after treatment. Making the treatment comparison results available to you, will help you find the most effective prostate cancer treatment.

Use this Data to Talk to Your Doctor About Your Options

The Prostate Cancer Results Study Group Full Report is an excellent resource to use during patient-doctor discussions. The report is available from the Foundation for a suggested $25 donation.

Help other men make better treatment decisions.

A $25 donation today helps us continue the groundbreaking working of the Prostate Cancer Treatment Study Group.